![]() |
市場調查報告書
商品編碼
1349826
HER2-low 轉移性乳癌 (mBC) 市場:初步研究 (KOL 見解) - 市場情報 - 流行病學和 2034 年市場預測HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2034 |
HER2低轉移性乳癌(mBC)市場以化療、內分泌治療和曲妥珠單抗deruxtecan(Enhertu)等標靶治療為主。到 2034 年,新興療法的採用將成為一個重大轉折點,將為 HER2 低轉移性乳癌藥物市場帶來巨大變化。在調查國家(美國、法國、德國、義大利、西班牙、英國和日本),用於治療 HER2 低轉移性乳癌的新興療法的銷售額預計在 2020 年至 2034 年的研究期間將出現強勁增長。預料到的。
HER2 低表達轉移性乳癌的治療似乎正在迅速發展。最近的臨床試驗表明,CDK4/6抑制劑與內分泌治療的組合作為標準一線治療是有效的。此外,PI3K抑制劑和AKT抑制劑的使用也在臨床試驗中進行研究,可能在不久的將來提供進一步的治療選擇。"
HER2 低表達的轉移性乳癌代表了乳癌認知和治療的重大轉變。歷史上,乳癌依 HER2 表現量分為 HER2 陽性或 HER2 陰性。然而,目前超過50%的乳癌被定義為“人類表皮生長因子受體2(HER2)低表達乳癌(BC)”,HER2免疫組織化學(IHC)評分為+1或+2,且螢光原位雜交(FISH)測試呈陰性。IHC/ISH 是目前用於定義 HER2 表達的唯一標準技術。最近的證據顯示 HER2 低表達乳癌可能是具有治療意義的目標亞群。
預計到 2034 年,G7 國家 HER2 低轉移性乳癌病例總數將顯著增加。據估計,到 2034 年,美國將成為 HER2 低轉移性乳癌發生率最高的國家。在歐盟五國中,德國的 HER2 低轉移性乳癌病例數最多,其次是英國、法國、義大利和西班牙。據報道,日本的治療病例數僅次於美國、德國和英國。
根據SEER資料庫,預計2022年美國將新診斷出287,850例女性乳癌,其中約50-60%的新診斷乳癌患者患有HER2低轉移性乳癌。確診。
HER2低表達轉移性乳癌治療市場預計將在研究期間(即2020年至2034年)經歷高速成長。與歐洲五國和日本相比,美國的市佔率最高。
本報告檢視了全球 HER2 低轉移性乳癌 (mBC) 市場,並提供了市場現狀以及病例量趨勢、患者趨勢、競爭產品市場定位和市場機會。
The HER2-Low Metastatic Breast Cancer (mBC) market is hugely contributed by chemotherapy, endocrine therapy and targeted therapy such as Trastuzumab deruxtecan (Enhertu). By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the HER2-Low Metastatic Breast Cancer therapeutics market. The sales of the emerging therapies for the treatment of HER2-Low Metastatic Breast Cancer in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2020-2034 study period.
"Experts believe that the treatment armamentarium for HER2-low metastatic breast cancer is rapidly evolving. Recent clinical trials have demonstrated the efficacy of CDK4/6 inhibitors in combination with endocrine therapy as a standard first-line treatment option. Additionally, the use of PI3K inhibitors and AKT inhibitors is being explored in clinical trials and may provide further treatment options in the near future."
The introduction of HER2-low metastatic breast cancer represents a significant shift in the understanding and treatment of breast cancer. Historically, breast cancers were categorized as either HER2-positive or HER2-negative based on the level of HER2 expression. However, more than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. IHC/ISH is the only standard technique currently applied to define HER2 expression. Recent evidence suggests that HER2-low breast cancer can be a targetable subgroup with potential therapeutic implications.
Report Attributes | Details |
Key Market Players: | Jiangsu HengRui Medicine; Duality Biologics; Yantai Rongchang Pharmaceutical; Gilead Sciences; AstraZeneca/Daiichi Sankyo. |
Forecast Period: | 2020-2034. |
Countries Covered: | US, France, Germany, Italy, Spain, UK, China and Japan. |
Current SOC: | Chemotherapy; Endocrine Therapies; Targeted Therapies. |
Future SOC: | Targeted Therapies; Combination Approach. |
Key Unmet Need: | Improved HER2 Assessment; Limited Treatment Option. |
Key Clinical Insights: | Emergence of HER2-low breast cancer has led to a significant change in treatment algorithms for patients with breast cancer. The introduction of targeted therapies like T-DXd offers new treatment options for patients who were previously considered to have limited options. |
Provider-Patient (PPP) Perspective: | Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options. |
The total incident cases of HER2-Low Metastatic Breast Cancer in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). As per estimates, the United States will present with the highest incidence of HER2-Low Metastatic Breast Cancer cases in 2034. Among the EU5, Germany had the highest HER2-Low Metastatic Breast Cancer cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States, Germany, and the UK.
According to SEER database estimates 287,850 new cases of female breast cancer will be diagnosed in 2022 in the U.S. Out of the newly diagnosed breast cancer patient, roughly 50-60% of patients is now diagnosed with HER2 Low metastatic Breast Cancer.
The HER2-Low Metastatic Breast Cancer therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034). The United States captured the highest market share as compared to the European 5 countries and Japan.
The current standard of care is limited to chemotherapy, endocrine and targeted therapy. In 2022, Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion is approved as the first targeted therapy for the treatment of patients with unresectable or metastatic HER2-low breast cancer in the United States and in 2023 in the European Union. This shift in treatment options has significant implications for the market. The changing treatment landscape has created new opportunities in the market for more companies to develop and commercialize the use of ADCs in HER2-low tumours. Additionally, the entrance of ADCs like Enhertu in the treatment paradigm of HER2-low breast cancer will also pave the way for diagnostic companies to develop the specific test for the identification of HER2-low breast cancer patient pool, which will be in turn increase the treated patient pool and will drive the market of HER2 low breast cancer significantly.
While the results of DESTINY-Breast04 study led to the breakthrough approval of Enhertu in the HER2 low breast cancer treatment space, it also changed the prescribing pattern among clinician's posing significant obstacles. These challenges include raising clinician awareness through education, updating practice guidelines, managing increasing treatment complexity, and addressing a lack of data surrounding the complex characteristics and temporal heterogeneity of HER2-low tumors.
In the 2024-2034 forecast period, there will be tremendous growth and shift in the therapeutic market with the launch of noble emerging therapies like Trastuzumab rezetecan (Jiangsu HengRui Medicine), DB-1303 (Duality Biologics), Disitamab vedotin (Yantai Rongchang Pharmaceutical), Sacituzumab Govitecan (Gilead Sciences), Datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo), MRG002 (Miracogen), and more. We expect a greater uptake of the new therapies which will result in better treatment outcomes for HER2-Low Metastatic Breast Cancer market space. The launch of these upcoming therapies will drive the highly competitive therapeutic market in the coming time.